Deciphering host genetics and viral determinants of MPOX epidemiology in the Democratic Republic of Congo (DECIPHER-MPOX)
- Funded by European & Developing Countries Clinical Trials Partnership (EDCTP)
- Total publications:0 publications
Grant number: 101194676
Grant search
Key facts
Disease
mpoxStart & end year
20242026Known Financial Commitments (USD)
$1,375,542Funder
European & Developing Countries Clinical Trials Partnership (EDCTP)Research Location
Congo (DRC), Uganda…Lead Research Institution
National Health Laboratory ServicesResearch Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnosticsResearch Subcategory
Pathogen morphology, shedding & natural historySpecial Interest Tags
N/AStudy Type
Non-ClinicalClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
UnspecifiedMpox Research Priorities
Pathogen: natural history, transmission and diagnostics, Epidemiological studies, Clinical characterisation and managementMpox Research Sub Priorities
Research for enhanced understanding of the disease, Promote improved understanding of the disease (including evidence synthesis)
Abstract
Background: Monkeypox virus (MPV) is a member of the Poxviridae family that includes smallpox, cowpox and chickenpox viruses. Endemic to equatorial Africa following casual human to animal or human to human transmission , recent events have seen an increased incidence with indications of sexual transmission. The disease is characterized by fever, muscle aches, skin rash, lymphadenopathy, oral sores, sore throat, cough, etc. Within any cluster of high risk contacts of a case mpox; however, not everyone exposed develops clinical disease. Moreover, among those contacts who develop mpox, not everyone gets severe disease or dies. Hypothesis: Host genetic & viral factors explain the differential outcomes following exposure to MPV. Objectives: To determine the host genetic and viral determinants of mpox disease in Kamituga area, South Kivu province, DRC. Specifically, we will (I) establish well phenotyped cohorts of house-hold contacts, (II) determine rare variants via family trios; (III) undertake RNASeq for transcriptomics, and (IV) study differential cellular immunity profiles using digital cell sorting (DCS) , (V) identify viral variants that drive severe disease Methods: Whole exome sequencing (WES), transcriptomics and DCS studies of house-family contacts clinically prequalified by PCR and serological testing. Virus gDNA will be reverse transcribed from sequenced host RNA and characterized by comparative genomics and phylogeny. Potential impact: This project will elucidate host genetic & viral determinants of susceptibility to mpox disease in context of natural exposure and infection; that may serve as correlates of immune protection following vaccination.